{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:47:48Z","timestamp":1785908868108,"version":"3.56.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jiac.2026.103021","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:52:33Z","timestamp":1782229953000},"page":"103021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Respiratory syncytial virus outcomes and duration of protection following nirsevimab administration in high-risk infants: a real-world study under year-round epidemic circulation in Japan"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3492-8566","authenticated-orcid":false,"given":"Yasuka","family":"Kimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-6957","authenticated-orcid":false,"given":"Masatoshi","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4910-9101","authenticated-orcid":false,"given":"Misuzu","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3148-9892","authenticated-orcid":false,"given":"Katsuya","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-1528","authenticated-orcid":false,"given":"Narutaka","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2590-7820","authenticated-orcid":false,"given":"Shinya","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-4597","authenticated-orcid":false,"given":"Hisaaki","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7993-1964","authenticated-orcid":false,"given":"Eriko","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8144-9525","authenticated-orcid":false,"given":"Kazuko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jiac.2026.103021_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2222\/jsv.55.77","article-title":"Respiratory syncytial virus","volume":"55","author":"Tsutsumi","year":"2005","journal-title":"Uirusu"},{"issue":"3","key":"10.1016\/j.jiac.2026.103021_bib2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0022-3476(05)90000-0","article-title":"Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric investigators collaborative network on infections in Canada","volume":"121","author":"Navas","year":"1992","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.jiac.2026.103021_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/ped.70307","article-title":"Spatial and temporal variability of respiratory syncytial virus disease seasonality in Japan, 2012-2024","volume":"68","author":"Arashiro","year":"2026","journal-title":"Pediatr Int"},{"issue":"3 Pt 1","key":"10.1016\/j.jiac.2026.103021_bib4","first-page":"531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","year":"1998","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.jiac.2026.103021_bib5","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.6.2400046","article-title":"Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024","volume":"29","author":"L\u00f3pez-Lacort","year":"2024","journal-title":"Euro Surveill"},{"issue":"3","key":"10.1016\/j.jiac.2026.103021_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400275","article-title":"Nirsevimab effectiveness at preventing RSV-related hospitalization in infants","volume":"4","author":"Jabagi","year":"2025","journal-title":"NEJM Evid"},{"issue":"8","key":"10.1016\/j.jiac.2026.103021_bib7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study","volume":"24","author":"Ares-G\u00f3mez","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2026.103021_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fpubh.2019.00039","article-title":"Detection of the onset of the epidemic period of respiratory syncytial virus infection in Japan","volume":"7","author":"Yamagami","year":"2019","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.jiac.2026.103021_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/piae115","article-title":"Nationwide epidemiology and outpatient healthcare resource use of children with respiratory syncytial virus from 2005 to 2021","volume":"14","author":"Okubo","year":"2025","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"1","key":"10.1016\/j.jiac.2026.103021_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13052-024-01627-8","article-title":"An epidemiological investigation of high-risk infants for respiratory syncytial virus infections: a retrospective cohort study","volume":"50","author":"Servadio","year":"2024","journal-title":"Ital J Pediatr"},{"issue":"6","key":"10.1016\/j.jiac.2026.103021_bib11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1067\/mpd.2000.110531","article-title":"Rates of hospitalization for respiratory syncytial virus infection among children in medicaid","volume":"137","author":"Boyce","year":"2000","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jiac.2026.103021_bib12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","year":"1998","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.jiac.2026.103021_bib13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.jiac.2026.103021_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jiac.2026.103021_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jiac.2026.103021_bib16","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/vaccines12060640","article-title":"Impact of nirsevimab immunization on pediatric hospitalization rates: a systematic review and meta-analysis (2024)","volume":"12","author":"Ricc\u00f2","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.jiac.2026.103021_bib17","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2352-4642(24)00171-8","article-title":"Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in paris, France","volume":"8","author":"Carbajal","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"10.1016\/j.jiac.2026.103021_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106652","article-title":"Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database","volume":"91","author":"Kitano","year":"2025","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.jiac.2026.103021_bib19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S2352-4642(25)00102-6","article-title":"180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial","volume":"9","author":"Munro","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"5","key":"10.1016\/j.jiac.2026.103021_bib20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1473-3099(25)00742-X","article-title":"Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study","volume":"26","author":"Razzini","year":"2026","journal-title":"Lancet Infect Dis"},{"issue":"14","key":"10.1016\/j.jiac.2026.103021_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.15585\/mmwr.mm7214a1","article-title":"Seasonality of respiratory syncytial virus - united States, 2017-2023","volume":"72","author":"Hamid","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:10:06Z","timestamp":1785906606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1341321X26001194"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103021","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Respiratory syncytial virus outcomes and duration of protection following nirsevimab administration in high-risk infants: a real-world study under year-round epidemic circulation in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103021"}}